In another CD22 CAR-T cell study in China, 34 B-ALL patients relapsed after CD19 CAR-T cell therapy, whereas 70% CR rates (24/34) were achieved after CD22 CAR-T cell therapy17. Here, CD22 is linked to acute lymphoblastic leukemia.